Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14401MR)

This product GTTS-WQ14401MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14401MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4568MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ4480MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ5446MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ12804MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ20MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ4429MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ13697MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ4517MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW